Natanel Barookhian: NavDx aids in the detection of HPV-driven cancers with unparalleled accuracy and specificity

Natanel Barookhian, Founder of TECHU, shared a post on X:

“Naveris first earned our attention and investment in 2019, amidst the development of their pioneering liquid biopsy test, NavDx. As the first and only blood test of its kind to be clinically validated, NavDx aids in the detection of HPV-driven cancers with unparalleled accuracy and specificity.
Recently, the company celebrated a significant achievement: receiving the Advanced Diagnostic Laboratory Test (ADLT) designation from the Centers for Medicare and Medicaid Services. This prestigious recognition marks a major milestone toward achieving the broad accessibility required for saving lives at scale.
Congratulations to Piyush Gupta, James McNally, and the entire Naveris Inc team. We are proud of the impact you are making on the world.”

Further details.

Source: Natanel Barookhian/X